ValuEngine downgraded shares of Affimed (NASDAQ:AFMD) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday morning.
AFMD has been the subject of several other research reports. BMO Capital Markets upped their price objective on shares of Affimed from $4.00 to $5.00 and gave the company an outperform rating in a research note on Tuesday, August 28th. Zacks Investment Research upgraded shares of Affimed from a sell rating to a hold rating in a research note on Tuesday, June 19th. Jefferies Financial Group upgraded shares of Affimed from a hold rating to a buy rating and upped their price objective for the company from $1.80 to $4.00 in a research note on Tuesday, August 28th. Finally, BidaskClub upgraded shares of Affimed from a strong sell rating to a sell rating in a research note on Friday, August 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $3.75.
NASDAQ AFMD opened at $4.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.33 and a current ratio of 5.36. Affimed has a 1 year low of $1.15 and a 1 year high of $7.35.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: How to Track your Portfolio in Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.